Lantheus Q2 Revenue Beats, But Guidance Suspended Amid $8B Curium Buyout

summarizeSummary

Lantheus beat Q2 estimates with $388.2M in revenue and $1.55 adjusted EPS, but suspended guidance due to its pending $8B acquisition by Curium. The quarter included a $30M charge for a China license repurchase and a non-cash gain from reduced contingent liabilities after an FDA setback for LNTH-2501.

check_boxKey Events · Earnings and Guidance · LNTH

• Q2 Revenue and EPS Beat

  Revenue of $388.2M (+2.7% YoY) and adjusted EPS of $1.55 topped consensus, driven by Neuraceq sales and DEFINITY volume growth, partially offset by lower PYLARIFY net pricing.

• Guidance Suspended

  All forward guidance was withdrawn due to the pending acquisition by Curium, which is expected to close in H1 2027 at $102.50/share cash plus up to $12.00/share in CVRs.

• $30M China License Repurchase

  Sales and marketing expenses jumped to $82.8M from $41.0M, primarily due to a $30M accrual to repurchase the DEFINITY license in China from its distributor.

• Non-Cash G&A Benefit from CRL

  G&A expenses fell to $20.6M from $66.5M, largely due to a $31.8M non-cash gain from revaluing contingent consideration liabilities lower after the FDA's Complete Response Letter for LNTH-2501.

auto_awesomeAnalysis · LNTH · Life Sciences

Lantheus delivered a strong Q2 with revenue of $388.2M and adjusted EPS of $1.55, both beating consensus. However, the company suspended all forward guidance, citing the pending $8 billion acquisition by Curium. The quarter also saw a $30M charge for repurchasing the DEFINITY license in China, a sharp drop in G&A expenses due to a non-cash gain from contingent consideration revaluation, and the fallout from the FDA's Complete Response Letter for LNTH-2501. With the merger expected to close in the first half of 2027, the focus shifts entirely to deal completion and the realization of contingent value rights.